News | March 23, 2024
USFDA grants ODD to Cevidoplenib for immune thrombocytopenia
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
To accelerate the development of next-generation radioconjugates to treat cancer
Additional capacity broadens Grace’s fine chemical capabilities for API production
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
Subscribe To Our Newsletter & Stay Updated
